We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Solventum (SOLV) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Solventum (SOLV - Free Report) will report quarterly earnings of $1.50 per share in its upcoming release, pointing to a year-over-year increase of 6.4%. It is anticipated that revenues will amount to $1.96 billion, exhibiting a decrease of 5.3% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Solventum metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Net Sales- MedSurg' stands at $1.21 billion. The estimate suggests a change of +3.3% year over year.
Based on the collective assessment of analysts, 'Net Sales- Health Information Systems' should arrive at $349.83 million. The estimate suggests a change of +4.1% year over year.
The combined assessment of analysts suggests that 'Net Sales- Dental Solutions' will likely reach $327.13 million. The estimate suggests a change of +3.9% year over year.
The collective assessment of analysts points to an estimated 'Operating Income- MedSurg' of $211.96 million. The estimate is in contrast to the year-ago figure of $208.00 million.
According to the collective judgment of analysts, 'Operating Income- Health Information Systems' should come in at $121.30 million. The estimate compares to the year-ago value of $114.00 million.
Analysts expect 'Operating Income- Dental Solutions' to come in at $77.64 million. The estimate compares to the year-ago value of $73.00 million.
Solventum shares have witnessed a change of -7.6% in the past month, in contrast to the Zacks S&P 500 composite's +1.8% move. With a Zacks Rank #3 (Hold), SOLV is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Curious about Solventum (SOLV) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Solventum (SOLV - Free Report) will report quarterly earnings of $1.50 per share in its upcoming release, pointing to a year-over-year increase of 6.4%. It is anticipated that revenues will amount to $1.96 billion, exhibiting a decrease of 5.3% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Solventum metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Net Sales- MedSurg' stands at $1.21 billion. The estimate suggests a change of +3.3% year over year.
Based on the collective assessment of analysts, 'Net Sales- Health Information Systems' should arrive at $349.83 million. The estimate suggests a change of +4.1% year over year.
The combined assessment of analysts suggests that 'Net Sales- Dental Solutions' will likely reach $327.13 million. The estimate suggests a change of +3.9% year over year.
The collective assessment of analysts points to an estimated 'Operating Income- MedSurg' of $211.96 million. The estimate is in contrast to the year-ago figure of $208.00 million.
According to the collective judgment of analysts, 'Operating Income- Health Information Systems' should come in at $121.30 million. The estimate compares to the year-ago value of $114.00 million.
Analysts expect 'Operating Income- Dental Solutions' to come in at $77.64 million. The estimate compares to the year-ago value of $73.00 million.
View all Key Company Metrics for Solventum here>>>Solventum shares have witnessed a change of -7.6% in the past month, in contrast to the Zacks S&P 500 composite's +1.8% move. With a Zacks Rank #3 (Hold), SOLV is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .